About US
Contact us
-
J&J, AbbVie's Imbruvica breaks into larger CLL market with first-line FDA nodJohnson & Johnson ($JNJ) and AbbVie ($ABBV) have snagged the indication for standout cancer med Imbruvica that they've been waiting for. On Friday, the FDA granted the pair a first-line nod in ch2016/3/7
-
Roche looks beyond Tamiflu, striking deal for Shionogi's flu fighterRoche's ($RHHBY) sometimes-blockbusterTamifluis one of only a couple of drugs approved for fighting influenza. But with generic competition brewing for the drug, the Swiss drugmaker is looking to the2016/3/7
-
Omalizumab drug can be better targeted to treat people with severe asthmaAround five million people in the UK are currently being treated for asthma. Of these, a quarter of a million are unable to get good control of their condition, resulting in frequent, severe, or even2016/3/3
-
Bass associate accuses PTO officials of bias against their pharma patent crusadeHedge funderKyle Bassand his Coalition for Affordable Drugs has been somewhat successful at using a new type of patent challenge to push review of "questionable" drug patents. But Bass' partner in tha2016/3/3
-
Digital health: the future for medicine?"The best way to predict the future is to invent it," these were the words of Alan Kay quoted by Dr Euan Ashley at the Recent Developments in Digital Health 2016 event at the Royal Society of Medicine2016/3/1
-
Are we ageing healthily? An interview with Professor Carol JaggerWith population ageing occurring in many countries, are rises in life expectancy resulting in increases in good quality years of life? This is the million dollar question but it is hard to give a def2016/3/1
-
Changes in use of anemia drugs affects risk of death or cardiovascular events in dialysis patientsA new study examines whether recent changes in the use of anemia drugs for patients on dialysis have contributed to changes in rates of death or cardiovascular events. The findings, which appear in an2016/2/29
-
New report explores strategies involved in developing and commercializing FDC productsFixed dose combination (FDC) products, which have been around for many years, can have both clinical and commercial advantages. Successful FDC products require thoughtful planning, beginning early in2016/2/29
-
Look out, drugmakers: NICE is taking the reins of England's Cancer Drugs FundBack in August, the National Institute of Health and Care Excellence (NICE) said it would take the reins of England's Cancer Drugs Fund (CDF) in light of the fund's continued financial problems. Now t2016/2/29
-
Pfizer receives FDA approval for Xeljanz XR to treat rheumatoid arthritisPfizer has received the US Food and Drug Administration (FDA) approval for its Xeljanz XR (tofacitinib citrate) extended-release tablets for the treatment of rheumatoid arthritis (RA). Xeljanz XR is2016/2/26